Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ALDX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Michael Alfieri Principal Financial Officer | ALDX Aldeyra Therapeutics, Inc. | Buy | 10,000 | $0.65 | $6,500 Buy | Form 4 ↗ |
| Nov 11, 2026 | Richard Douglas Director | ALDX Aldeyra Therapeutics, Inc. | Buy | 200,000 | $0.6445 | $128.9K Buy | Form 4 ↗ |
| Jun 3, 2026 | Todd C. Brady President and CEO, Director | ALDX Aldeyra Therapeutics, Inc. | Buy | 250,000 | $1.67 | $417.5K Buy | Form 4 ↗ |
| Mar 19, 2026 | Richard Douglas Director | ALDX Aldeyra Therapeutics, Inc. | Buy | 70,000 | $1.40 | $98.0K Buy | Form 4 ↗ |
| Mar 18, 2026 | Michael Alfieri Principal Financial Officer | ALDX Aldeyra Therapeutics, Inc. | Buy | 5,000 | $1.42 | $7,100 Buy | Form 4 ↗ |
| Aug 13, 2025 | Michael Alfieri Principal Financial Officer | ALDX Aldeyra Therapeutics, Inc. | Buy | 2,500 | $5.30 | $13.3K Buy | Form 4 ↗ |
| Aug 11, 2025 | Stephen Machatha Chief Development Officer | ALDX Aldeyra Therapeutics, Inc. | Sale | 22,073 | $5.15 | $113.7K Sale | Form 4 ↗ |
| Apr 3, 2025 | Perceptive Life Sciences Master Fund Ltd 10% owner | ALDX Aldeyra Therapeutics, Inc. | Sale | 3.40M | $1.42 | $4.8M Sale | Form 4 ↗ |
| Apr 12, 2023 | Nancy Miller-Rich Director | ALDX Aldeyra Therapeutics, Inc. | Buy | 509 | $10.13 | $5,156 Buy | Form 4 ↗ |
| May 3, 2021 | Nancy Miller-Rich Director | ALDX Aldeyra Therapeutics, Inc. | Buy | 413 | $12.81 | $5,291 Buy | Form 4 ↗ |
10 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:16 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances